Shawn Iadonato - 23 Jun 2025 Form 4 Insider Report for KINETA, INC./DE (KANT)

Role: Director
Signature: /s/ Nanette Agustines, as Attorney-in-Fact
Issuer symbol: KANT
Transactions as of: 23 Jun 2025
Net transactions value: +$75,026
Form type: 4
Filing time: 26 Jun 2025, 19:50:50 UTC
Previous filing: 05 Sep 2024
Next filing: 02 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Iadonato Shawn	Director	C/O KINETA, INC., 7683 SE 27TH STREET, SUITE 481, MERCER ISLAND	/s/ Nanette Agustines, as Attorney-in-Fact	26 Jun 2025	0001958184

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership
transaction	KANT	Common Stock	Options Exercise	$7,638	+12,500	+1.9%	$0.6110	687,730	23 Jun 2025	Direct
transaction	KANT	Common Stock	Options Exercise	$81,000	+225,000	+33%	$0.3600	912,730	23 Jun 2025	Direct
transaction	KANT	Common Stock	Tax liability	$13,612	-52,353	-5.7%	$0.2600	860,377	23 Jun 2025	Direct
holding	KANT	Common Stock						8,553	23 Jun 2025	By IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KANT	Stock Option (Right to Buy)	Options Exercise	$0	-12,500	-100%	$0.000000	0	23 Jun 2025	Common Stock	12,500	$0.6110	Direct	F1
transaction	KANT	Stock Option (Right to Buy)	Options Exercise	$0	-225,000	-100%	$0.000000	0	23 Jun 2025	Common Stock	225,000	$0.3600	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.

Content

Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.